Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Myristyl nicotinate (Tetradecyl nicotinate) 是 Nicotinic acid 的亲脂衍生物,是一种酯前药。它能够刺激光损伤的皮肤中的表皮分化,增加皮肤 NAD 含量并增强人皮肤屏障。它被开发用于将烟酸输送到皮肤中,以防止光化性角化病及其发展为皮肤癌。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
50 mg | ¥ 327 | 现货 | ||
100 mg | ¥ 460 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 387 | 现货 |
产品描述 | Myristyl nicotinate (Tetradecyl nicotinate) is an ester prodrug being developed for delivery of nicotinic acid (NIC) into the skin for prevention of actinic keratosis and its progression to skin cancer. |
体外活性 | Myristyl nicotinate is an ester prodrug under development for delivery of nicotinic acid to skin for treatment and prevention of conditions that involve skin barrier impairment such as chronic photodamage and atopic dermatitis or for mitigating skin barrier impairment that results from therapy such as retinoids or steroids[1].?The formulation stability of Myristyl nicotinate is crucial because even small amounts of free nicotinic acid cause skin flushing, an effect that is not harmful but would severely limit tolerability[1]. |
体内活性 | Retinoic acid therapy resulted in stratum corneum thinning of approximately 25% (P = 0.006 versus baseline) that was ameliorated by Myristyl nicotinate use (P < 0.005). Therapy resulted in an increased rate of transepidermal water loss (TEWL) of approximately 45% (P = 0.001 versus baseline) and use of Myristyl nicotinate protected against the increase in TEWL with the strongest protection provided by prior use of Myristyl nicotinate (P = 0.056 versus placebo). Myristyl nicotinate use reduced the incidence of side-effects of the therapy and again prior use provided the greatest reduction of side-effects. Subjects showed statistically significant clinical improvement (P < 0.05 versus baseline) during the study. Myristyl nicotinate use did not interfere with any clinical improvement parameters and improved effects on temple laxity (P = 0.01 versus placebo). Analysis of changes in epidermal thickness, Ki67-positive cells and intensity of loricrin staining demonstrated that Myristyl nicotinate either improved or did not interfere with retinoic acid efficacy. These results show that prior and concurrent use of Myristyl nicotinate can mitigate barrier impairment and improve the tolerability of retinoic acid therapy for facial photodamage without interfering with efficacy[1]. |
别名 | Tetradecyl nicotinate, 肉豆蔻醇烟酸酯 |
分子量 | 319.48 |
分子式 | C20H33NO2 |
CAS No. | 273203-62-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 15 mg/mL (46.95 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.1301 mL | 15.6504 mL | 31.3009 mL | 78.2522 mL |
5 mM | 0.626 mL | 3.1301 mL | 6.2602 mL | 15.6504 mL | |
10 mM | 0.313 mL | 1.565 mL | 3.1301 mL | 7.8252 mL | |
20 mM | 0.1565 mL | 0.7825 mL | 1.565 mL | 3.9126 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Myristyl nicotinate 273203-62-6 Endocrinology/Hormones GPCR/G Protein GPR Nicotinic acid ester inhibit Tetradecyl nicotinate delivery 肉豆蔻醇烟酸酯 impairment Inhibitor derivative lipophilic skin barrier prodrug inhibitor